Search Result

Results for "

pain-related diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Apoptosis (2) Autophagy (2) Bacterial (1) Biochemical Assay Reagents (1) COX (3) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (2) Hydroxycarboxylic Acid Receptor (HCAR) (1) Isotope-Labeled Compounds (1) Melanocortin Receptor (3) Neurokinin Receptor (1) Opioid Receptor (3) Reference Standards (4) Sodium Channel (6) TRP Channel (4) VAP-1 (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (12) Metabolic Disease (3) Neurological Disease (21)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0451

Acacetin Maximum Cited Publications 13 Publications Verification 5,7-Dihydroxy-4'-methoxyflavone	Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Cancer
Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-N0637

Eriodictyol Maximum Cited Publications 13 Publications Verification Huazhongilexone	Melanocortin Receptor TRP Channel	Infection Inflammation/Immunology
Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

HY-N0637A

(±)-Eriodictyol (±)-Huazhongilexone; Dihydroluteolin	Melanocortin Receptor TRP Channel	Metabolic Disease
(±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

HY-W050088

Isoxepac HP 549	Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-155635

Nav1.8-IN-4	Sodium Channel	Infection
Nav1.8-IN-4 (compound 9a) is a Nav1.8 channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases .

HY-W010989

Gly-His-Lys acetate	Biochemical Assay Reagents Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Gly-His-Lys acetate is a natural, circulating regulatory and antimicrobial tripeptide derived from extracellular matrix proteins. Gly-His-Lys acetate binds Cu ²⁺ to support copper enzyme activation, antioxidant processes, cellular bioenergetics, and the synthesis of elastin, collagen and catecholamines. Gly-His-Lys acetate regulates cell growth, differentiation and tissue repair, and exerts regenerative, anxiolytic, anti-inflammatory, analgesic and immunosuppressive activities. Gly-His-Lys acetate induces liver degenerative changes. Gly-His-Lys acetate can be used for the research of infections, anxiety, pain-related behaviors and immune-associated liver diseases .

HY-B2121

6-Methoxy-2-naphthoic acid 6-MNA; Naproxen impurity O	Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds .

HY-403593

FCH-2296413	Hydroxycarboxylic Acid Receptor (HCAR)	Neurological Disease
FCH-2296413 is a potent and selective hydroxycarboxylic acid receptor (HCAR) agonist with an EC₅₀ of 4.4-8.6 nM. FCH-2296413 exhibits analgesic activity and can be used for the research of peripheral pain-related diseases .

HY-143721

SSAO inhibitor-2	VAP-1	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SSAO inhibitor-2 is a selective semicarbazide-sensitive amine oxidase (SSAO/VAP-1) inhibitor with an IC₅₀ of < 10 nM. SSAO inhibitor-2 can be used for the research of inflammation diseases, diabetes and diabetes-related diseases, mental disorders, pain-related diseases, ischemic diseases, vascular diseases, ocular diseases, fibrosis, neuroinflammatory diseases, cancer, and tissue transplant rejection .

HY-Z7640

4-Desmethyl-2-methyl celecoxib	COX	Inflammation/Immunology
4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis .

HY-N0451R

Acacetin (Standard) Maximum Cited Publications 13 Publications Verification 5,7-Dihydroxy-4'-methoxyflavone (Standard)	Reference Standards Apoptosis Autophagy	Neurological Disease Inflammation/Immunology Cancer
Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-W050088S

Isoxepac-d6 HP 549-d₆	Isotope-Labeled Compounds Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-160593

Nav1.8-IN-12	Sodium Channel	Neurological Disease
Nav1.8-IN-12 (Compound 23 R) is a Nav1.8 channel inhibitor. Nav1.8-IN-12 can be used in the study of pain-related diseases .

HY-158979

Nav1.8-IN-14	Sodium Channel	Neurological Disease
Nav1.8-IN-14 (compound 20) is a potent and selective Nav1.8 inhibitor. Nav1.8-IN-14 can be used in the study of pain-related diseases .

HY-162246

Nav1.8-IN-5	Sodium Channel	Cardiovascular Disease Neurological Disease
Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research .

HY-129931

Phenylalanylphenylalanylamide H-Phe-Phe-NH2	Neurokinin Receptor	Neurological Disease
Phenylalanylphenylalanylamide (H-Phe-Phe-NH₂) is a ligand for the substance P 1–7 (SP_1-7) binding site with a K_i value of 1.5 nM. Phenylalanylphenylalanylamide exerts significant anti-allodynic and anti-hyperalgesic effects in animal models of neuropathic pain following central administratio. Phenylalanylphenylalanylamide shows no distinct effect after peripheral (intraperitoneal) administration. Phenylalanylphenylalanylamide can be used for research on pain-related diseases .

HY-114235

SCP-1	Drug Intermediate	Neurological Disease
SCP-1 (Compound C-1) is the key intermediate for synthesizing the non-opioid analgesic drug SRP-3D (DA). SCP-1 can be used for the research of neurological disease, such as pain-related diseases .

HY-142919

μ opioid receptor agonist 2	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 2 （Compound H-3）is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .

HY-142918

μ opioid receptor agonist 1	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 1 （Compound H-1a）is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MOR receptor agonist and can be used for the research of pain and pain related diseases .

HY-N0637AR

(±)-Eriodictyol (Standard) (±)-Huazhongilexone (Standard); Dihydroluteolin (Standard)	Reference Standards Melanocortin Receptor TRP Channel	Metabolic Disease
3-Chlorobenzoic acid (Standard) is the analytical standard of 3-Chlorobenzoic acid. This product is intended for research and analytical applications. (±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

HY-B2121R

6-Methoxy-2-naphthoic acid (Standard) 6-MNA (Standard); Naproxen impurity O (Standard)	Reference Standards Drug Metabolite COX	Neurological Disease Inflammation/Immunology
6-Methoxy-2-naphthoic acid (Standard) (6-MNA (Standard)) is the analytical standard of 6-Methoxy-2-naphthoic acid (HY-B2121). This product is intended for research and analytical applications. 6-Methoxy-2-naphthoic acid (6-MNA) is the active metabolite of Nabumetone (HY-B0559). 6-Methoxy-2-naphthoic acid is also an inhibitor of COX-1 and COX-2. 6-Methoxy-2-naphthoic acid can inhibit the synthesis of gastric mucosal prostaglandin E₂. 6-Methoxy-2-naphthoic acid can be used in the research of inflammation and pain-related diseases. In addition, 6-Methoxy-2-naphthoic acid is an impurity in Naproxen (HY-15030) and can also be used in the synthesis of other active compounds.

HY-183652

5-HT2C-agonist-14	5-HT Receptor Sodium Channel	Neurological Disease
5-HT2C-agonist-14 is a 5-HT2C receptor agonist with an EC₅₀ of 2.9 μM against human receptors. It also acts as a voltage-gated sodium channel inhibitor with blood-brain barrier permeable. 5-HT2C-agonist-14 elevates seizure threshold, suppresses seizure progression and alleviates pain-related behaviors. It can be used in the research of epilepsy and pain-related diseases .

HY-183646

Nav1.8-IN-23	Sodium Channel	Neurological Disease
Nav1.8-IN-23 is a Na_v1.8 voltage-gated sodium channel inhibitor with a pIC₅₀ of 6.1. Nav1.8-IN-23 can be used for the research of pain-related diseases .

HY-182782

Analgesic agent-4	Adenosine Receptor	Neurological Disease
Analgesic agent-4 is an adenosine A₃AR ligand with analgesic/antinociceptive activity. Analgesic agent-4 inhibits writhing responses in mice and exhibits dose-dependent activity in the acetic acid (HY-Y0319)-induced mouse writhing model. Analgesic agent-4 can be used in the research of pain-related diseases .

HY-W050088R

Isoxepac (Standard) HP 549 (Standard)	Reference Standards Drug Derivative	Neurological Disease Inflammation/Immunology
Isoxepac (Standard) (HP 549 (Standard)) is the analytical standard of Isoxepac (HY-W050088). This product is intended for research and analytical applications. Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

HY-W158948

6-Fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole	Opioid Receptor	Neurological Disease
6-Fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole is a ORL-1 receptor modulator. 6-Fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole regulates downstream pathways associated with nociception, cognition and physiological processes. 6-Fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole is used in the research of central nervous system diseases and pain-related disorders including anxiety, depression, Alzheimer's disease and attention deficit disorder .

HY-165459

KJM429 MK-056	TRP Channel	Infection Inflammation/Immunology
KJM429 (MK-056) is a high-affinity ligand for the rat vanilloid receptor rTRPV1 (K_i=30-63 nM) with a unique dual regulatory function. KJM429 acts as a competitive antagonist to inhibit TRPV1 receptor activation induced by Capsaicin (HY-10448), resiniferatoxin, thermal stimulation and weak acid (pH 6.0), and switches to a TRPV1 agonist under strong acid conditions (pH<5.5). KJM429 effectively blocks calcium influx induced by Capsaicin and partial thermal stimulation, and triggers calcium uptake under low pH conditions, with minimal effects on non-TRPV1-mediated calcium signaling. KJM429 can be used for research on the mechanisms of pain-related diseases such as postherpetic neuralgia, diabetic neuropathy, cluster headache, osteoarthritis and pruritus .

Cat. No.	Product Name

HY-L139

Pain-Related Compound Library	3,291 compounds
Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot. MCE supplies a unique collection of 3,291 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Pain-Related Compound Library

3,291 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 3,291 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0451

Acacetin Maximum Cited Publications 13 Publications Verification 5,7-Dihydroxy-4'-methoxyflavone	Neurological Disease Classification of Application Fields Flavones Anti-aging Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis Autophagy
Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-N0637

Eriodictyol Maximum Cited Publications 13 Publications Verification Huazhongilexone	Structural Classification Classification of Application Fields Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids other families Flavonones Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification	Melanocortin Receptor TRP Channel
Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

HY-N0637A

(±)-Eriodictyol (±)-Huazhongilexone; Dihydroluteolin	Structural Classification Flavonoids Lawsonia inermis L. Lythraceae Flavones Plants Source Classification	Melanocortin Receptor TRP Channel
(±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

HY-N0451R

Acacetin (Standard) Maximum Cited Publications 13 Publications Verification 5,7-Dihydroxy-4'-methoxyflavone (Standard)	Neurological Disease Classification of Application Fields Anti-aging Dendranthema morifolium (Ramat.) Tzvel. Plants Compositae Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Inflammation/Immunology Disease Research Fields Source Classification	Reference Standards Apoptosis Autophagy
Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research .

HY-N0637AR

(±)-Eriodictyol (Standard) (±)-Huazhongilexone (Standard); Dihydroluteolin (Standard)	Structural Classification Flavonoids Lawsonia inermis L. Lythraceae Flavones Plants Source Classification	Reference Standards Melanocortin Receptor TRP Channel
3-Chlorobenzoic acid (Standard) is the analytical standard of 3-Chlorobenzoic acid. This product is intended for research and analytical applications. (±)-Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. (±)-Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. (±)-Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. (±)-Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. (±)-Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases .

Cat. No.	Product Name	Chemical Structure

HY-W050088S

Isoxepac-d6
Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

Isoxepac-d6

Isoxepac-d₆ (HP 549-d₆) is the deuterium labeled Isoxepac (HY-W050088). Isoxepac (HP 549) is an orally active non-steroidal anti-inflammatory agent. Isoxepac can inhibit Carrageenan (HY-125474) paw oedema, adjuvant-induced polyarthritis, and prostaglandin synthesis. Isoxepac (200 mg) has an analgesic effect after meniscectomy with a low incidence of side effects. Isoxepac can be used in the research of inflammatory (rheumatoid arthritis) and pain-related diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks